These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23992230)

  • 21. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
    Butrym A; Łacina P; Rybka J; Chaszczewska-Markowska M; Mazur G; Bogunia-Kubik K
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):151-156. PubMed ID: 28083618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
    Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
    BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cereblon (
    Iskierka-Jażdżewska E; Canzian F; Stępień A; Martino A; Campa D; Stein A; Krawczyk-Kuliś M; Rybicka-Ramos M; Kyrcz-Krzemień S; Butrym A; Mazur G; Jurczyszyn A; Zawirska D; Grząśko N; Tomczak W; Subocz E; Wątek M; Pasiarski M; Rymko M; Całbecka M; Druzd-Sitek A; Walewski J; Kruszewski M; Raźny M; Zaucha JM; Dudziński M; Gaj P; Robak T; Warzocha K; Jamroziak K
    Leuk Lymphoma; 2020 Mar; 61(3):699-706. PubMed ID: 31746254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of cereblon levels by anti-myeloma agents.
    Díaz-Rodríguez E; Pandiella A
    Leuk Lymphoma; 2016; 57(1):167-76. PubMed ID: 25860244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
    Eichner R; Heider M; Fernández-Sáiz V; van Bebber F; Garz AK; Lemeer S; Rudelius M; Targosz BS; Jacobs L; Knorn AM; Slawska J; Platzbecker U; Germing U; Langer C; Knop S; Einsele H; Peschel C; Haass C; Keller U; Schmid B; Götze KS; Kuster B; Bassermann F
    Nat Med; 2016 Jul; 22(7):735-43. PubMed ID: 27294876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
    Lopez-Girona A; Heintel D; Zhang LH; Mendy D; Gaidarova S; Brady H; Bartlett JB; Schafer PH; Schreder M; Bolomsky A; Hilgarth B; Zojer N; Gisslinger H; Ludwig H; Daniel T; Jäger U; Chopra R
    Br J Haematol; 2011 Aug; 154(3):325-36. PubMed ID: 21707574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.
    Butrym A; Rybka J; Łacina P; Gębura K; Frontkiewicz D; Bogunia-Kubik K; Mazur G
    Leuk Res; 2015 Dec; 39(12):1462-6. PubMed ID: 26521987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
    Broyl A; Kuiper R; van Duin M; van der Holt B; el Jarari L; Bertsch U; Zweegman S; Buijs A; Hose D; Lokhorst HM; Goldschmidt H; Sonneveld P; ;
    Blood; 2013 Jan; 121(4):624-7. PubMed ID: 23233657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
    Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
    Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
    Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
    Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical significance of cereblon expression in multiple myeloma.
    Schuster SR; Kortuem KM; Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Ahmann G; Kumar S; Rajkumar SV; Mikhael J; Laplant B; Champion MD; Laumann K; Barlogie B; Fonseca R; Bergsagel PL; Lacy M; Stewart AK
    Leuk Res; 2014 Jan; 38(1):23-8. PubMed ID: 24129344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
    Kuwahara-Ota S; Shimura Y; Steinebach C; Isa R; Yamaguchi J; Nishiyama D; Fujibayashi Y; Takimoto-Shimomura T; Mizuno Y; Matsumura-Kimoto Y; Tsukamoto T; Chinen Y; Kobayashi T; Horiike S; Taniwaki M; Gütschow M; Kuroda J
    Br J Haematol; 2020 Dec; 191(5):784-795. PubMed ID: 32558939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
    Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
    Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon.
    Wang B; Li M; Cao D; Sun Q; Yu W; Ma J; Ren H; Xu G; Zhou L
    Cell Mol Life Sci; 2024 Aug; 81(1):349. PubMed ID: 39136771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.
    Zhou N; Gutierrez-Uzquiza A; Zheng XY; Chang R; Vogl DT; Garfall AL; Bernabei L; Saraf A; Florens L; Washburn MP; Illendula A; Bushweller JH; Busino L
    Leukemia; 2019 Aug; 33(8):2006-2021. PubMed ID: 30760870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
    Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C; Komurov K; MacBeth K; Starczynowski DT
    Nat Med; 2016 Jul; 22(7):727-34. PubMed ID: 27294874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
    Burslem GM; Ottis P; Jaime-Figueroa S; Morgan A; Cromm PM; Toure M; Crews CM
    ChemMedChem; 2018 Aug; 13(15):1508-1512. PubMed ID: 29870139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.